Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19.

Autor: Gregory DJ; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA.; Pediatric Infectious Disease, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Vannier A; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA., Duey AH; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA., Roady TJ; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA., Dzeng RK; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA., Pavlovic MN; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA., Chapin MH; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA., Mukherjee S; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA., Wilmot H; Cardiology Care Clinics, Eatonton, GA, USA., Chronos N; Cardiology Care Clinics, Eatonton, GA, USA., Charles RC; Harvard Medical School, Boston, MA, USA.; Division of Infectious Diseases, Massachusetts General Hospital Boston, Boston, MA, USA.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Ryan ET; Cardiology Care Clinics, Eatonton, GA, USA.; Division of Infectious Diseases, Massachusetts General Hospital Boston, Boston, MA, USA.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA., LaRocque RC; Harvard Medical School, Boston, MA, USA.; Division of Infectious Diseases, Massachusetts General Hospital Boston, Boston, MA, USA., Miller TE; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Garcia-Beltran WF; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Thierauf JC; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Iafrate AJ; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Mullenbrock S; Cell Signaling Technology, Danvers, MA, USA., Stump MD; Cell Signaling Technology, Danvers, MA, USA., Wetzel RK; Cell Signaling Technology, Danvers, MA, USA., Polakiewicz RD; Cell Signaling Technology, Danvers, MA, USA., Naranbhai V; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Poznansky MC; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Virulence [Virulence] 2022 Dec; Vol. 13 (1), pp. 890-902.
DOI: 10.1080/21505594.2022.2073025
Abstrakt: Antibodies to SARS-CoV-2 are central to recovery and immunity from COVID-19. However, the relationship between disease severity and the repertoire of antibodies against specific SARS-CoV-2 epitopes an individual develops following exposure remains incompletely understood. Here, we studied seroprevalence of antibodies to specific SARS-CoV-2 and other betacoronavirus antigens in a well-annotated, community sample of convalescent and never-infected individuals obtained in August 2020. One hundred and twenty-four participants were classified into five groups: previously exposed but without evidence of infection, having no known exposure or evidence of infection, seroconverted without symptoms, previously diagnosed with symptomatic COVID-19, and recovered after hospitalization with COVID-19. Prevalence of IgGs specific to the following antigens was compared between the five groups: recombinant SARS-CoV-2 and betacoronavirus spike and nucleocapsid protein domains, peptides from a tiled array of 22-mers corresponding to the entire spike and nucleocapsid proteins, and peptides corresponding to predicted immunogenic regions from other proteins of SARS-CoV-2. Antibody abundance generally correlated positively with severity of prior illness. A number of specific immunogenic peptides and some that may be associated with milder illness or protection from symptomatic infection were identified. No convincing association was observed between antibodies to Receptor Binding Domain(s) (RBDs) of less pathogenic betacoronaviruses HKU1 or OC43 and COVID-19 severity. However, apparent cross-reaction with SARS-CoV RBD was evident and some predominantly asymptomatic individuals had antibodies to both MERS-CoV and SARS-CoV RBDs. Findings from this pilot study may inform development of diagnostics, vaccines, and therapeutic antibodies, and provide insight into viral pathogenic mechanisms.
Databáze: MEDLINE